---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-085188"
form_type: "8-K"
ticker: "RIGL"
cik: "0001034842"
company_name: "RIGEL PHARMACEUTICALS INC"
filed_at: "2022-08-02T23:59:59+00:00"
generated_at: "2026-06-24T05:39:04.016433+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Rigel Q2 TAVALISSE net product sales $18.6M; licenses olutasidenib from Forma; draws $10M term loan

## Summary
- TAVALISSE net product sales of $18.6M, up 9% YoY; total revenues $29.8M; net loss $13.5M ($0.08/share).
- Exclusive license from Forma for olutasidenib (mIDH1 inhibitor) for R/R AML; $2M upfront, up to $233M milestones; PDUFA Feb 15, 2023.
- Amended MidCap credit agreement: extended maturity to Sept 2026, interest-only to Oct 2024; drew $10M fourth tranche term loan.
- Completed enrollment (280 patients) in Phase 3 COVID-19 trial of fostamatinib; top-line data expected Q4 2022.
- Knight license for TAVALISSE in Latin America: $2M upfront, up to $20M milestones; Kissei NDA submitted in Japan for ITP.

## SEC filing metadata
- accession: 0001104659-22-085188
- form_type: 8-K
- ticker: RIGL
- cik: 0001034842
- company_name: RIGEL PHARMACEUTICALS INC
- filed_at: 2022-08-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.02, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1034842/000110465922085188/0001104659-22-085188-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1034842/000110465922085188/tm2222339d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-085188
- JSON: https://secwatch.observer/filing/0001104659-22-085188.json
- Plain text: https://secwatch.observer/filing/0001104659-22-085188.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.